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Introduction
Ovarian cancer is the second most important type of 
pelvic tumor in women. Worldwide up to 240 000 
women are diagnosed with ovarian cancer each year 
(WHO, 2014). As signs and symptoms in early 
ovarian cancer are scarce, up to 63% of patients are 
diagnosed at stage III or IV, leading to poor prognosis 
(Vergote et al., 2010). Until now, prognosis is based 
on the histological type, grade and the staging 
according to the FIGO classification. 
Gynecological ultrasound has proven very useful 
and accurate in the diagnosis of ovarian cancer, 
though is subjective. Over the past decade, large 
progress has been made to standardize and optimize 
the classification of adnexal masses by the Inter­
national Ovarian Tumour Analysis (IOTA) group, 
by means of logistic regression models. Meta­
analyses and external validation studies have shown 
superiority of the IOTA models (Van Calster et al., 
2014). In contrast, no serum marker has shown to be 
specific enough in the diagnosis of adnexal masses 
as a standalone. However, the most recent model of 
the IOTA group, the ADNEX model, combines 
ultrasound characteristic, clinical data and a serum 
marker, CA125 (Table I). (Van Calster et al., 2014). 
Whole body Magnetic Resonance Imaging (MRI) 
with diffusion weighting is an advantage in the 
preoperative staging of patients with ovarian cancer, 
providing important information about retro peri­
toneal and thoracic nodes (Michielsen et al., 2014). 
However in the diagnosis of difficult to classify 
adnexal masses the advantage of MRI compared to 
transvaginal ultrasound by experts is limited (Kaijser 
et al., 2014).
So far, research on prognostic markers has 
focused on genetic markers influencing survival and 
treatment response in ovarian cancer. In 1996 the 
first reports were published that suggested that 
BRCA1/2 germline mutation is correlated with 
improved outcome (Rubin et al., 1996). This was 
underscored by a recent systematic review (Sun et 
al., 2014). Recently, a generalized genetic mapping 
of high­grade serous ovarian cancer was performed 
by the Cancer Genome Atlas Network (TCGA). 
They created 4 subtypes based on mutation analysis, 
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shown that a high ratio of Teff compared to 
immunosuppressive Treg in the tumor is associated 
with better prognosis (Zhang et al., 2003; Curiel 
et al., 2004). It has become clear that merely the 
presence of Teff is not enough, the balance between 
Teff and immunosuppressive cells is important. In a 
study in metastatic melanoma, Teff were isolated 
from the tumor microenvironment and analyzed. 
Immediately after isolation they showed a sub­
optimal cytokine production and proliferation, 
however this was normalized when these T cells 
were expanded ex vivo and stimulatory cytokines 
were added (Harlin et al., 2006). This underlines the 
importance of the immunosuppressive tumor micro­
environment. 
Immunosuppressive cells in general
Regulatory T cells (Treg) are a subpopulation of T 
cells, which maintain tolerance to self­antigens by 
influencing the activity of other Teff. Their 
physiological function is to prevent auto­immunity 
and down regulate undesired T cell responses. We 
can differentiate between 2 subsets of regulatory T 
cells. The naturally occurring Treg develop in the 
thymus and are responsible for central inhibition of 
auto­immunity. T cells that leave the bone marrow 
migrate to the thymus to mature. In the thymus auto­
reactive T cells are deleted. Adaptive Treg develop 
as a consequence of continued peripheral T cell 
activation, as is present in chronic inflammation and 
tumor development. Treg are trafficked to the tumor 
site through presence of chemokines such as CCL2 
and CCL22 in the tumor microenvironment. 
Expansion of Tregs can be induced by tolerogenic 
dendritic cells (DCs) through the expression of 
indoleamine 2,3­dioxygenase (IDO). Transforming 
epidermal growth factor beta (TGF­β) can convert 
effector T cells into regulatory T cells leading to 
further increase immunosuppression (Gajewski et 
mRNA and miRNA expression and DNA methyl­
ation: immunoreactive, differentiated, pro liferative 
and mesenchymal. T­cell chemokine ligands 
CXCL11 and CXCL10 and the receptor CXCR3 
characterized the immunoreactive subtype (The 
Cancer Genome Atlas Research Network, 2011). 
This article highlights the importance of the immune 
system in ovarian cancer. Indeed, once malignant 
cells arise, the immune system will control their 
development mainly by the presence of effector T 
cells (Teff). This stage is called the immune 
surveillance. If the operation is success ful, the 
malignant cells are eliminated or reside in a dormant 
state (elimination vs equilibrium). However, cells 
might also escape the control of the immune system, 
start proliferating and the tumor becomes clinically 
apparent (Schreiber et al., 2011). The tumor develops 
several strategies to evade the immune system. First 
and most important is the attraction of immuno­
suppressive cells into the tumor. In the tumor 
microenvironment there is a rise in immuno­
suppressive cells and molecules that render the Teff 
less functional. Most important players seem to be 
regulatory T cells (Treg), myeloid derived suppressor 
cells (MDSC) and tumor­associated macrophages 
(TAM). As a second line of defense the tumor 
inhibits the infiltration of Teff into the tumor through 
a decrease in chemotactic molecules and a decreased 
quality of the tumoral vascularization. Current 
research in onco­immunology is focusing on 
methods to overcome this immune­escape. 
It is clear that the immune system is an important 
regulator in the development of cancer. It can be 
presumed that the determination of these immune 
cells might give rise to new diagnostic and even 
prognostic markers for ovarian cancer. Early 
research in colorectal cancer suggests that the 
presence of Teff in the tumor might be more 
important than traditional staging to predict outcome 
(Galon et al., 2006). In ovarian cancer it has been 
Table I. — Criteria used in the IOTA ADNEX model.Age of the patient at examination YearsReferral center for Gynecological Oncology Yes/NoMaximal diameter of the lesion mmMaximal diameter of the largest solid part mmMore than 10 locules Yes/NoNumber of papillary projections NoneOne/Two/ThreeMore than threeAcoustic shadow present Yes/NoAscites (outside the pelvis) Yes/NoSerum CA-125 U/mL
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Myeloid derived suppressor cells (MDSCs) are a 
heterogeneous population of early myeloid pro­
genitors at different stages of differentiation. These 
cells are capable of suppressing the innate (natural 
killer cells (NK)/non­specific defense) and the 
adaptive immune system (Teff/specific defense 
mechanisms). MDSC are influenced by pro­
inflammatory cytokines and their presence in the 
tumor microenvironment could be one of the causes 
of tumor­associated immunosuppression. The 
presence of circulating MDSC correlates with poor 
prognosis, increased metastatic potential and tumor 
evasion of host immunity. As depicted in Figure 2, 
the accumulation of MDSC in the tumor micro­
environment is stimulated by several factors such 
as: granulocyte macrophage colony stimulating 
factor (GM­CSF), vascular endothelial growth 
factor (VEGF), chemokines such as CCL­2 and 
TGF­β, produced by the tumor and the intratumoral 
immune cells (Nagaraj et al., 2010; Talmadge et al., 
2013). MDSC will recruit and induce Treg through 
production of IL­10 and TGF­β and the expression 
of chemotactic molecules on the cell surface of the 
MDSC. MDSC are myeloid lineage cells and can 
differentiate into DC when matured; however 
al., 2013). Treg exert their immunosuppressive 
function through several mechanisms as depicted in 
Figure 1 (Zou, 2006). Treg will promote IDO 
expression and lead to depletion of tryptophan. This 
leads to T cell anergy and apoptosis of T cells. 
Furthermore stimulation of IDO will also stimulate 
a feedback loop by inducing tolerogenic DCs (Katz 
et al., 2008). Treg will also increase their expression 
of negative co­stimulatory molecules, such as 
Programmed Death­1 (PD­1), Programmed Death 
Ligand 1(PD­L1) and CTLA­4, leading to increased 
apoptosis in Teff (Ooi et al., 2014). Treg will also 
secrete IL­10 and TGF­β. IL­10 is an anti­
inflammatory cytokine that will cause dysfunction 
of antigen presenting cells (APC) through decreased 
expression of MHC molecules and other co­
stimulatory molecules and a decrease in circulating 
IL­12 (Maloy et al., 2001; Zheng et al., 2004). 
Secretion of TGF­β causes unresponsiveness in 
tumor infiltrating effector T cells through FoxP1 
transcription factor expression (Zheng et al., 2004; 
Stephen et al., 2014). Parallel to IDO, TGF­β 
expression will stimulate an immunosuppressive 
feedback­loop to stimulate the transformation of 
Teff to Treg (Zou, 2006).
Fig. 1. — The role of regulatory T cells (Treg) in the tumor microenvironment: a schematic overview of the most important 
immunosuppressive mechanisms through which regulatory T cells function and the possibility of feedback­loops. Indoleamine 
2,3­dioxygenase (IDO) is an intracellular enzyme that catalyses the oxidative catabolism of tryptophan. IDO suppresses T cell 
responses and promotes immune tolerance in mammalian pregnancy, tumor resistance, chronic infection, autoimmunity and allergic 
inflammation. TGF­β: transforming growth factor­β; APC: antigen presenting cell; MHC: major histocompatibility complex; 
CD: cluster of differentiation.
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M1 macrophages and immunosuppressive M2 
macrophages. Once attracted to the tumor we often 
see a switch from M1 to M2 macrophages. Because 
of this switch, the role of TAM in the tumor­
microenvironment is complex. The physiological 
role of M1 macrophages is pathogen clearance and 
antigen presentation to NK cells and T cells, which 
leads to activation of the adaptive immune system. 
On the other hand, M2 macrophages have a low 
phagocytic capacity and will not properly stimulate 
NK cells and T cells. They will even counteract the 
immune response by producing immunosuppressive 
molecules, leading to poor prognosis with an 
increased number of TAM.
Intratumoral TAM are in general immuno­
suppressive and will inhibit an anti­tumoral immune 
response. Differentiation of monocytes into M1 
macrophages is promoted by interferon­γ, lipo­
polysaccharide (LPS) and other microbial products, 
leading to killing of bacteria, immunostimulatory 
functions and anti­tumor cytotoxicity (Sica et al., 
2008). The major factors causing the switch from 
immunostimulatory M1 macrophages to immuno­
suppressive M2 macrophages in the tumor micro­
environment are hypoxia, macrophage colony 
stimulating factor­1 (CSF­1), TGF­β, IL­4, IL­13 
and the presence of apoptosis (Noy et al., 2014). As 
shown in Figure 3 there are several mechanisms by 
influenced by the tumor environment they will lead 
to tolerogenic IDO­producing DCs (Gabrilovich et 
al., 2012). MDSC will inhibit NK cells and cause T 
cell anergy through the production of TGF­β. As 
TGF­β is also one of the molecules that will attract 
MDSC this will again cause a positive feedback 
loop. MDSC will also inhibit the function of NK 
cells through interaction with their NK cell receptor 
NKp30. Therefore MDSC are the main negative 
regulator of NK cell function in a tumor­bearing 
host (Hoechst et al., 2009; Li et al., 2009). The main 
immunosuppressive role of MDSCs is the inhibition 
of T cell activation and proliferation. In general 
tumor­associated MDSC will deprive T cells of 
amino­acids, such as L­arginine necessary for their 
proliferation. MDSC will inhibit activation of the T 
cell through oxidation or nitrosylation of the T­cell 
receptor. Furthermore MDSCs will interfere with T 
cell migration and viability (Gabrilovich et al., 
2012).
Tumor-associated macrophages (TAM) are a 
type of white blood cells that engulf and digest 
cellular debris, foreign substances, bacteria and 
cancer cells by phagocytosis. Macrophages play a 
critical role in innate immunity and help initiate 
the adaptive immune response by recruiting other 
immune cells such as lymphocytes. We can generally 
classify TAM in two categories: immunostimulatory 
Fig. 2. — The role of Myeloid Derived Supressor Cells (MDSC) in the tumor microenvironment: an overview of the most relevant 
immunomodulatory functions of tumor associated myeloid derived suppressor cells stimulating immunosuppressive cells and inhibiting 
anti­tumor effector cells. Treg: regulatory T cell; DC: dendritic cell; NK cell: natural killer cell.
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survival. PD­L1 expression on tumor cells was 
shown to be an independent variable correlated with 
poor survival (Hamanishi et al., 2007). To date no 
studies have been able to correlate immuno sup­
pressive serum markers, such as TGF­β andIL­10 
at diagnosis with prognosis (Mustea et al., 2009; 
Tas et al., 2014). A recent study correlated VEGF, 
survivin and second mitochondria­derived activator 
of caspase (Smac/DIABLO) serum levels to poor 
prognosis. Survivin and Smac/DIABLO are inhi­
bitors of apoptosis (Dobrzycka et al., 2015).
Future perspectives
The discovery of the importance of the immune 
system in the development of cancer can help us in 
the determination of new diagnostic and prognostic 
parameters. An advantage of the determination of an 
immunophenotype, compared to genetic differ en­
tiation, is bifold. When mapping the immuno­
suppressive phenotype we do not only take into 
account the characteristics of the tumor, but also the 
environment in which the tumor grows. Clinically, 
this tumor environment is very relevant, as we know 
that patients with HIV, patients on immuno­
suppressive drugs against transplant rejection, … 
are prone to malignancies and have a worse prog­
nosis. A second advantage is the possibility of using 
serum markers instead of biopsies. This evades the 
possibility of non­representative biopsies, inter­
metastasis­heterogeneity and might be able to avoid 
invasive diagnostic techniques.
which M2 macrophages cause immunosuppression. 
M2 macrophages have shown an enhanced expres­
sion of IL­10, leading to decreased expression of 
IL­12 and co­stimulatory molecules by APC (Laoui 
et al., 2014; Ruffell et al., 2014). M2 macro phages 
will inhibit Teff through stimulation of IDO and 
increased secretion of TGF­β (Sica et al., 2008). M2 
macrophages will also increase neo­vasculo genesis 
through increased secretion of VEGF, which con­
versely will also increase polarization towards M2 
(Noy et al., 2014). Furthermore, M2 macro phages 
will also increase CCL­22, a chemokine that attracts 
Treg and MDSC to the tumor micro environment 
(Curiel et al., 2004). These feedback­loops that 
strengthen the immunosuppressive micro environ­
ment in the tumor, making it nearly impossible for 
Teff to significantly reduce tumor volume.
Immunosuppressive cells in ovarian cancer: situ-
ation at diagnosis
The prognostic value of immunosuppressive cells in 
ovarian cancer has been rarely studied. The available 
literature focuses merely on the presence of immune 
cells in the tumor rather than on their systemic 
presence in blood. A recent meta­analysis by Hwang 
et al has shown a significant survival advantage 
linked to tumor­infiltrating lymphocytes (TIL), 
however this biomarker is not yet used in clinical 
practice, possibly due to differences in definition of 
TIL (Hwang et al., 2012). Curiel et al. (2004) studied 
intra­tumoral Treg, which correlated with a reduced 
Fig. 3. — Macrophages in the tumor microenvironment. M1 macrophages are immunostimulatory cells that produce high amounts 
of nitric oxide (NO) and reactive oxygen intermediates to effectively destroy tumor cells. Through the L­arginine pathway M2 
macrophages will inhibit the NO production of M2 macrophages and produce an anti­inflammatory response.[ HYPERLINK \l “Sic08” 
1 Teff: effector T cell; NK cell: natural killer cell; TGF­β: transforming growth factor­β; APC: antigen presenting cell; MHC: major 
histocompatibility complex; CD: cluster of differentiation; IDO: Indoleamine 2,3­dioxygenase; MDSC: myeloid derived suppressor 
cell; VEGF: vascular endothelial growth factor. 
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Treg, MDSC and TAM are detectable in blood 
and their secreted compounds are detectable in 
serum. It might thus be relevant to try to detect these 
cells in women with suspected ovarian masses. Just 
like CA125 in the ADNEX model, these cells or 
their metabolites might be a useful partner with 
added value to our existing diagnostic tools. And 
maybe on the long run, it will even be possible to 
differentiate patients into different subtypes, 
reflecting a different immunosuppressive signature, 
representing a possibility to improve outcome 
through tailored approaches.
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